title: [Clinical path for mFOLFOX6 describing criteria for reduction and suspension of drugs].
abstract: Clinical path for executing mFOLFOX6 in an outpatient chemotherapy room was settled on for the aim of standardization and common information with medical staffs about mFOLFOX6. The feature of this clinical path is described doses of drugs, results of laboratory examination, criteria for deciding adverse effects, common adverse effects and management, criteria for reduction and suspension of oxaliplatin and 5-fluorouracil. Patients before induction of the clinical path were compared with patients after that about relative dose intensity (RDI), reasons why treatments were suspended and progression-free survival (PFS). Fifty eight patients after induction were significantly higher RDI of oxaliplatin than 108 patients before induction (p=0.04). There were no significant differences about a frequency of suspension due to adverse effects (p=0.18) and PFS (p=0.74). The clinical path that we settled on was considered useful not only for common information with medical staffs but also for standardization.
authors.affiliation: Dept. of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University.
authors.forename: Norimichi
authors.initials: N
authors.lastname: Okada
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Ishibashi
authors.forename: Tomonori
authors.initials: T
authors.lastname: Ohsawa
authors.forename: Jun
authors.initials: J
authors.lastname: Sobajima
authors.forename: Kouki
authors.initials: K
authors.lastname: Kuwabara
authors.forename: Toru
authors.initials: T
authors.lastname: Ishiguro
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Amano
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hatano
authors.forename: Naoko
authors.initials: N
authors.lastname: Hokama
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Tajima
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Ishii
authors.forename: Youzou
authors.initials: Y
authors.lastname: Yokoyama
authors.forename: Azusa
authors.initials: A
authors.lastname: Yamamoto
authors.forename: Kensuke
authors.initials: K
authors.lastname: Kumamoto
authors.forename: Norihiro
authors.initials: N
authors.lastname: Haga
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000068258:Bevacizumab; D003110:Colonic Neoplasms / Q000188:drug therapy*; D019091:Critical Pathways; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil